Dear RayBiotech Technical Support Team, I am writing to inquire about the compatibility and application protocol of the Human Insulin / Insulin R Ligand Binding Assay / Inhibitor Screening ELISA Kit (Catalog No: BAH-INSR-INS) for testing various long-acting insulin analogues, specifically Insulin Detemir, Insulin Degludec, and Insulin Glargine. Before proceeding with our experiments, we would appreciate your technical guidance on the following points: Detection Antibody Cross-Reactivity:Does the Detection Antibody (Item C) included in this kit exhibit cross-reactivity with long-acting insulin analogues (Detemir, Degludec, and Glargine)? If so, what is the approximate percentage of cross-reactivity compared to native human regular insulin? Detection Specificity in Competitive Assay:Since this is a competitive binding assay, does the Detection Antibody discriminate between the Kit’s Ligand Protein (Item F) and the added test analogue? If the antibody recognizes both the reference insulin and the test analogue bound to the receptor, could you please clarify how the signal inhibition is correctly resolved without background signal from the bound test analogue? Buffer Compatibility for Lipid/Hexameric Formulations: For Insulin Detemir: Given Detemir’s high binding affinity to serum albumin, does the 1X Assay Diluent contain BSA or other protein blockers that might interfere with Detemir binding? Do you recommend a BSA-free buffer protocol for Detemir? For Insulin Degludec: Does RayBiotech have a recommended sample preparation protocol (e.g., addition of mild detergents or chelating agents like EDTA) to dissociate multi-hexamers into monomers prior to the competition step? Protocol Optimization:Are there any validated protocol modifications or application notes available for assessing $IC_{50}$ or Relative Binding Affinity (RBA) for modified insulin analogues using this kit? Thank you for your time and assistance. I look forward to your detailed response. Best regards,

Review by yasaman salimi, from tarbiat modares university, on Sep 22, 2026